









市場行情
/
股票
/
nasdaq-pepg
/

PepGen Inc

PEPG

5.308USD

-0.132-2.43%

交易中（美東）報價延遲15分鐘

364.91M總市值

虧損本益比TTM



PepGen Inc

5.308

-0.132-2.43%

概覽公司財務分析

概覽

公司

財務

分析

關於 PepGen Inc 公司

PepGen Inc. is a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies. The Company’s Enhanced Delivery Oligonucleotide (EDO) platform leverages cell-penetrating peptides to improve the uptake and activity of conjugated oligonucleotide therapeutics. Its EDO peptides are engineered to optimize tissue penetration, cellular uptake and nuclear delivery. Using these EDO peptides, the Company is generating a pipeline of oligonucleotide therapeutic candidates designed to target the root cause of serious diseases. It is focused on addressing the underlying cause of Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1), which have high unmet need. Its pipeline consists of two clinical stage programs, PGN-EDO51 for DMD patients who are amenable to an exon 51-skipping approach and PGN-EDODM1 for DM1 patients, and several additional preclinical stage programs. Its product candidates also include PGN-EDO53, PGN-EDO45 and PGN-EDO44.

PepGen Inc簡介



公司代碼PEPG

公司名稱PepGen Inc

上市日期May 06, 2022

CEOMcArthur (James G)

員工數量81

證券類型Ordinary Share

年結日May 06

公司地址245 Main St, 2nd Floor

城市CAMBRIDGE

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United States of America

郵編02142

電話17034568000

網址https://pepgen.com

公司代碼PEPG

上市日期May 06, 2022

CEOMcArthur (James G)

PepGen Inc公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. James G. Mcarthur, Ph.D.

President, Chief Executive Officer, Director

53.19K

+3040.14%

Ms. Laurie Bartlett Keating, J.D.

Independent Chairman of the Board

4.17K

Ms. Mary Beth Delena, J.D.

General Counsel, Company Secretary

1.43K

-8.67%

Mr. Habib Joseph Dable

Independent Director

Ms. Heidi Henson, CPA

Independent Director

Dr. Paul D. Streck, M.D.

Executive Vice President, Head of Research & Development

Mr. Noel P. Donnelly

Chief Financial Officer

Dr. Joshua B. (Josh) Resnick, M.D.

Independent Director

Dr. Howard Mayer, M.D.

Independent Director

Dr. Kasra Kasraian, Ph.D.

Chief Technology Officer

名稱

名稱/職務

職務

持股

持股變動

Dr. James G. Mcarthur, Ph.D.

President, Chief Executive Officer, Director

53.19K

+3040.14%

Ms. Laurie Bartlett Keating, J.D.

Independent Chairman of the Board

4.17K

Ms. Mary Beth Delena, J.D.

General Counsel, Company Secretary

1.43K

-8.67%

Mr. Habib Joseph Dable

Independent Director

Ms. Heidi Henson, CPA

Independent Director

Dr. Paul D. Streck, M.D.

Executive Vice President, Head of Research & Development

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 11月18日週二

持股股東

股東類型

持股股東

佔比

RA Capital Management, LP

29.19%

Oxford Science Enterprises PLC

7.21%

Viking Global Investors LP

5.07%

Commodore Capital LP

3.43%

Vivo Capital, LLC

3.38%

其他

51.73%

持股股東

佔比

RA Capital Management, LP

29.19%

Oxford Science Enterprises PLC

7.21%

Viking Global Investors LP

5.07%

Commodore Capital LP

3.43%

Vivo Capital, LLC

3.38%

其他

51.73%

股東類型

持股股東

佔比

Venture Capital

40.87%

Hedge Fund

24.67%

Investment Advisor/Hedge Fund

14.63%

Investment Advisor

7.70%

Sovereign Wealth Fund

1.81%

Private Equity

1.21%

Research Firm

0.85%

Individual Investor

0.18%

其他

8.09%

機構持股



更新時間: 10月1日週三

報告期間

機構數

持股數

持股佔比

持股變動

2025Q3

157

41.73M

60.71%

+1.86M

2025Q2

165

31.28M

95.59%

-5.47M

2025Q1

168

31.44M

96.09%

-5.26M

2024Q4

160

31.09M

95.12%

-3.10M

2024Q3

156

31.41M

96.35%

-1.62M

2024Q2

150

31.22M

97.59%

-974.84K

2024Q1

140

30.76M

96.24%

+4.98M

2023Q4

127

22.26M

93.52%

+3.25M

2023Q3

124

22.70M

95.37%

+3.35M

2023Q2

119

23.17M

97.35%

+3.81M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

RA Capital Management, LP

20.06M

29.19%

+9.38M

+87.70%

Sep 26, 2025

Oxford Science Enterprises PLC

4.96M

7.21%

+200.00K

+4.21%

Sep 30, 2025

Viking Global Investors LP

3.48M

5.07%

+2.00M

+134.91%

Sep 26, 2025

Point72 Asset Management, L.P.

2.76M

4.01%

+83.23K

+3.11%

Jun 30, 2025

Laurion Capital Management LP

810.76K

1.18%

Jun 30, 2025

The Vanguard Group, Inc.

937.02K

1.36%

+37.29K

+4.14%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

ProShares Ultra Nasdaq Biotechnology

0.03%

iShares Micro-Cap ETF

0.02%

Invesco Nasdaq Biotechnology ETF

0.02%

iShares Biotechnology ETF

0.01%

Proshares Ultra Russell 2000

Invesco Dorsey Wright SmallCap Momentum ETF

ProShares UltraPro Russell2000

ProShares Hedge Replication ETF

DFA Dimensional US Sustainability Core 1 ETF

Dimensional US Core Equity 1 ETF

ProShares Ultra Nasdaq Biotechnology

佔比0.03%

iShares Micro-Cap ETF

佔比0.02%

Invesco Nasdaq Biotechnology ETF

佔比0.02%

iShares Biotechnology ETF

佔比0.01%

Proshares Ultra Russell 2000

佔比0%

Invesco Dorsey Wright SmallCap Momentum ETF

佔比0%

ProShares UltraPro Russell2000

佔比0%

ProShares Hedge Replication ETF

佔比0%

DFA Dimensional US Sustainability Core 1 ETF

佔比0%

Dimensional US Core Equity 1 ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

PepGen Inc的前五大股東是誰？



PepGen Inc的前五大股東如下：
RA Capital Management, LP
持有股份：20.06M
佔總股份比例：29.19%。
Oxford Science Enterprises PLC
持有股份：4.96M
佔總股份比例：7.21%。
Viking Global Investors LP
持有股份：3.48M
佔總股份比例：5.07%。
Point72 Asset Management, L.P.
持有股份：2.76M
佔總股份比例：4.01%。
Laurion Capital Management LP
持有股份：810.76K
佔總股份比例：1.18%。